GATA3 and intrahepatic cholangiocarcinoma: Whenever feasible, a targeted IHC/ICC panel (ER, PR, HER2 ± GATA3, mammaglobin, and GCDFP-15) helps confirm lineage and guide therapeutic decision-making.